These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 36208236

  • 1. [Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation].
    Huang YJ, Zhang JH, Dong CX, Kang JM, Hou YF, Zhang YF, Qi K, Yang LH.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1361-1368. PubMed ID: 36208236
    [Abstract] [Full Text] [Related]

  • 2. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
    Hu KX, Sun QY, Guo M, Qiao JX, Yu CL, Qiao JH, Dong Z, Sun WJ, Zuo HL, Huang YJ, Cai B, Ai HS.
    Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
    [Abstract] [Full Text] [Related]

  • 3. Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Zhu Y, Zhao H, Zhang X, Wu Y, Xie Y, Li Y, Lian Y, Huang J, Li J, Chen Y, Qian S.
    Biol Blood Marrow Transplant; 2017 May; 23(5):830-835. PubMed ID: 28189902
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
    Liu J, Jia JS, Gong LZ, Lu SY, Zhu HH, Huang XJ, Jiang H.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep 14; 39(9):734-738. PubMed ID: 30369183
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome].
    Mao JP, Xue LG, Zhu YX, Jia T, Wang Y, Miao L, Wei JF, Zhao LD.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr 14; 31(2):338-343. PubMed ID: 37096503
    [Abstract] [Full Text] [Related]

  • 7. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S, Li Z, Fu JH, Hu XH, Xu Y, Jin ZM, Tang XW, Han Y, Chen SN, Sun AN, Wu DP, Qiu HY.
    Asian Pac J Cancer Prev; 2015 Apr 14; 16(15):6627-32. PubMed ID: 26434886
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
    Li X, Dong Y, Li Y, Ren R, Wu W, Zhu H, Zhang Y, Hu J, Li J.
    BMC Cancer; 2019 Aug 20; 19(1):819. PubMed ID: 31429724
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C, Candoni A, Zannier ME, Olivieri J, Imbergamo S, Caizzi M, Nadali G, Di Bona E, Ermacora A, Gottardi M, Facchinelli D, Ciancia R, Lazzarotto D, Dubbini MV, Festini G, Gherlinzoni F, Michieli MG, Semenzato G, Fanin R.
    Leuk Res; 2019 Jan 20; 76():33-38. PubMed ID: 30529681
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia.
    Tao S, Zhou D, Song L, Deng Y, Chen Y, Ding B, He Z, Wang C, Yu L.
    Hematology; 2023 Dec 20; 28(1):2231733. PubMed ID: 37408450
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
    Wang L, Luo J, Chen G, Fang M, Wei X, Li Y, Liu Z, Zhang Y, Gao S, Shen J, Wang X, Gao X, Zhou W, Ma Y, Liu H, Li X, Yang L, Sun K, Yu L.
    Clin Epigenetics; 2020 Sep 01; 12(1):132. PubMed ID: 32873343
    [Abstract] [Full Text] [Related]

  • 17. [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
    Sun Y, Xu Y, Wu D, Shen H, Yang Z, Qiu H, Chen S, Sun A.
    Zhonghua Xue Ye Xue Za Zhi; 2015 Dec 01; 36(12):1025-30. PubMed ID: 26759106
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.